Clinical Trial Update: Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cabozantinib plus pembrolizumab as first-line therapy for cisplatin-ineligible advanced urothelial carcinoma; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Carcinoma

Drugs mentioned

• Cotellic (cobimetinib)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: University of Utah | Conditions: Metastatic Urothelial Carcinoma, Bladder Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-11-26